Articles - Drugs in Context

Corrigendum: Role of a topical hydrogel (Dermatix® wound care gel) in acute and chronic wound management: a case series of real-world experiences and expert opinion from Asia

Chin Yen Lee, Elizabeth Wei Hsi Chang, Khong Yik Chew, Vilvkumaran Karupayah, Wildan Latief, Vi Anh Le, Dohar Tobing, Thi Phuong Thao Vu, Kean Chew Wong

Article Type

Corrigendum

Published

17 Feb 2026

Antibiotic treatment for neonatal sepsis: changing trends and future directions

Genevieve PG Fung, Kam Lun E Hon, Alexander KC Leung

Article Type

Review

Published

12 Feb 2026

This article provides an updated review on the aetiology and diagnosis of neonatal sepsis, antibiotic management and antibiotic stewardship.

Real-world effectiveness of a phlebotonic formulation combining diosmin, Ruscus, Melilotus and Vitis vinifera on symptoms and quality of life in patients with chronic venous and lymphatic disease: results from the VIVEMA Stasis observational study

Giampiero Avruscio, Carmen Tirrito, Sonia Ragazzo, Mario Mangrella, Roberto Piazza, Erica Tanasi

Article Type

Original Research

Published

10 Feb 2026

The VIVEMA Stasis observational study was designed to evaluate the symptom burden, oedema reduction and quality of life in patients with chronic venous disease, lymphoedema and/or phlebolymphatic oedema treated with a phlebotonic formulation containing diosmin, Ruscus aculeatus, Melilotus officinalis and Vitis vinifera, combined with functional bandaging and elastic compression therapy.

Corrigendum: Primary hyperhidrosis: an updated review

Mahan Maazi, Alexander KC Leung, Joseph M Lam

Article Type

Corrigendum

Published

09 Feb 2026

The authors wish to make the following corrections to their article: Maazi M, Leung AKC, Lam JM. Primary hyperhidrosis: an updated review. Drugs Context. 2025;14:2025-3-2. https://doi.org/10.7573/dic.2025-3-2

Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir

Sarah L Anderson

Article Type

Review

Published

05 Feb 2026

Lenacapavir (LEN), a first in-class capsid inhibitor, is approved as a twice-yearly subcutaneous injection for HIV prevention and represents a major advance beyond daily oral and bi-monthly injectable long-acting pre-exposure prophylaxis regimens.